EUCTR2006-002517-12-IE进行中（未招募）不适用
A multicentre, single-arm, open-label expanded access study of lenalidomide plus dexamethasone in previously treated subjects with relapsed/refractory multiple myeloma
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Signed informed consent.
- •At least 18 years of age.
- •Able to adhere to the study visit schedule and other protocol requirements.
- •Relapsed/refractory multiple myeloma.
- •Measurable levels of myeloma protein in serum (=0.5 g/dL) or urine (=0.2 g / 24-hour collection sample).
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 2.
- •Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; and 3) for at least 28 days after discontinuation from the study. The two methods of reliable contraception must include one highly effective method (i.e. intrauterine device (IUD), hormonal [injections, or implants], tubal ligation, partner’s vasectomy) and one additional effective (barrier) method (i.e. latex condom, diaphragm, cervical cap). Combined oral contraceptive pills are not recommended because they carry an increased risk of venous thromboembolism. If a patient is currently using combined oral contraception switching to another adequate method of contraception should be considered. The risk of venous thromboembolism continues for 4-6 weeks after discontinuing combined oral contraception. If alternative methods are unacceptable, thromboprophylaxis should be considered while continuing combined oral contraception. The patient should be adequately informed about the risks of venous thromboembolism. FCBP must be referred to a qualified provider of contraceptive methods if needed.
- •Before starting study drug:
- •Female Subjects:
- •FCBP must have two negative pregnancy tests (sensitivity of at least 50 mIU/mL) prior to starting study drug. The first pregnancy test must be performed within 10-14 days prior to the start of study drug and the second pregnancy test must be performed within 24 hours prior to the start of study drug. The subject may not receive study drug until the Investigator has verified that the results of these pregnancy tests are negative.
- •Will be warned that sharing study drug is prohibited and will be counseled about pregnancy precautions and potential risks of fetal exposure.
- •Must agree to abstain from donating blood during study participation and for at least 28 days after discontinuation from the study.
- •Male Subjects:
- •Must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 28 days following discontinuation from the study even if he has undergone a successful vasectomy.
- •Will be warned that sharing study drug is prohibited and will be counseled about pregnancy precautions and potential risks of fetal exposure.
- •Must agree to abstain from donating blood, semen, or sperm during study participation and for at least 28 days after discontinuation from the study.
- •During study participation and for 28 days following discontinuation from the study:
- •All Subjects:
- •No more than a 28-day supply of study drug will be dispensed at a time.
- •Female Subjects:
- •FCBP with regular cycles must agree to have pregnancy tests weekly for the first 28 days of study participation and then every 28 days while on study, at study discontinuation, and at day 28 following discontinuation from the study. If menstrual cycles are irregular, the pregnancy testing must occur we
排除标准
- •Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
- •Pregnant or lactating females.
- •Prior therapy with lenalidomide
- •Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
- •Any of the following laboratory abnormalities:
- •- Absolute neutrophil count (ANC) <1,000 cells/mm^3 (1.0 x 10^9/L)
- •- Platelet count <75,000/mm^3 (75 x 10^9/L) for subjects in whom <50% of the bone marrow nucleated cells are plasma cells.
- •- Platelet count <30,000/mm3 (30x10^9/L) for subjects in whom >=50% of bone marrow nucleated cells are plasma cells.
- •- Serum creatinine >2.5 mg/dL (221 µmol/L)
- •- Serum SGOT/AST or SGPT/ALT >3.0 x upper limit of normal (ULN)
- •- Serum total bilirubin >2.0 mg/dL (34 µmol/L)
- •Prior history of malignancies other than multiple myeloma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for =1 year.
- •Known hypersensitivity to thalidomide or dexamethasone.
- •Prior history of uncontrollable side effects to dexamethasone therapy.
- •The development of a desquamating rash while taking thalidomide.
- •Neuropathy = Grade 2.
研究者
相似试验
进行中（未招募）
1 期
A multicenter, single-arm, open-label expanded access study of lenalidomide plus dexamethasone in previously treated subjects with relapsed/refractory Multiple Myeloma.EUCTR2006-002517-12-GBCelgene International Sàrl1,400
进行中（未招募）
1 期
AMG 510 Expanded Access Protocol in Selected European CountriesPreviously Treated Locally Advanced and Unresectable or Metastatic Non-small Cell Lung Cancer with KRAS p.G12C MutationMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-005279-11-ITAMGEN INC.638
进行中（未招募）
1 期
AMG 510 Expanded Access Protocol in Selected European CountriesPreviously Treated Locally Advanced and Unresectable or Metastatic Non-small Cell Lung Cancer with KRAS p.G12C MutationEUCTR2020-005279-11-ESAmgen, Inc.638
进行中（未招募）
1 期
This study is being done to learn more about long-term use of evolocumab, safety and tolerability, and whether its chronic administration is associated to any side effectsMedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861MedDRA version: 21.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861DyslipidemiaEUCTR2016-004066-26-SEAmgen Inc1,600
进行中（未招募）
1 期
A study assessing if long-term use of evolocumab will be safe, well tolerated, and whether it causes any side effects.DyslipidemiaMedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861MedDRA version: 21.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861EUCTR2015-004780-36-PLAmgen Inc5,000